KF
CLDX icon

Krilogy Financial’s Celldex Therapeutics CLDX Stock Holding History

Krilogy Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40
Closed – – 228
2018
Q3 		$0 Buy
+40
New +$280 ﹤0.01% 818
2018
Q2 		– Sell
-40
Closed -$1K – 237
2018
Q1 		$1K Hold
40
– – ﹤0.01% 727
2017
Q4 		$2K Hold
40
– – ﹤0.01% 680
2017
Q3 		$2K Hold
40
– – ﹤0.01% 726
2017
Q2 		$1K Hold
40
– – ﹤0.01% 690
2017
Q1 		$2K Hold
40
– – ﹤0.01% 641
2016
Q4 		$2K Hold
40
– – ﹤0.01% 641
2016
Q3 		$2K Hold
40
– – ﹤0.01% 657
2016
Q2 		$3K Hold
40
– – ﹤0.01% 645
2016
Q1 		$2K Buy
40
+13
+48% +$1.46K ﹤0.01% 598
2015
Q4 		$6K Hold
27
– – 0.01% 298
2015
Q3 		$4K Buy
+27
New +$7.64K ﹤0.01% 480

Other funds holding CLDX

CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Krilogy Financial's CLDX Position: Q4 2018 in Review

Krilogy Financial sold out of Celldex Therapeutics (CLDX) in Q4 2018, closing a stake of 40 shares.

Krilogy Financial first reported a position in CLDX in Q3 2015 and held it in 12 quarters. The position peaked at $6K in Q4 2015. 85 funds tracked by Wall St. Rank hold CLDX as of Q4 2018.

  • Krilogy Financial reported no remaining Celldex Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 40 Celldex Therapeutics shares in Q4 2018.
  • Krilogy Financial first reported a position in Celldex Therapeutics in Q3 2015 and held it in 12 quarters.
  • Krilogy Financial's Celldex Therapeutics position peaked at $6K in Q4 2015.
  • 85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.